We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Smartphone-Based Device Used for Influenza Virus Detection

By LabMedica International staff writers
Posted on 05 Aug 2019
A simple and inexpensive smartphone-based device was able to detect influenza virus particles in clinical samples with almost 100 times greater sensitivity than commercial rapid influenza diagnostic tests.

Droplet-based digital bioassays enable highly sensitive and quantitative analysis of biomolecules. More...
However, digital bioassays generally require fluorescence microscopy techniques for detection, which are too large, expensive, and slow for point-of-care testing.

Investigators at the University of Tokyo (Japan) recently descibed an alternative method for detection of viruses in clinical samples. For this purpose, they developed a simple smartphone-based mobile imaging platform (23 × 10 cenitmeters × seven centimeters high) for digital point-of-care bioassays.

The device was designed to trap virus particles on a clear surface in microwells of 48 femtoliters capacity illuminated by an LED lamp. When a virus became trapped inside the microwell, the incident light from the LED was redirected upwards into the camera lens, manifesting as a bright pixel in an otherwise dark field.

The investigators used the smartphone device for digital influenza virus counting (DIViC) based on a fluorogenic assay for neuraminidase activity of the virus. Distinct fluorescence spots derived from single virus particles were observed. The number of detected fluorescence spots correlated well against the virus titer, suggesting that high sensitivity and quantification were achieved. On the other hand, the mobile platform detected only about 60% of influenza virus particles that could be identified by conventional fluorescence microscopy. Nonetheless, digital influenza virus counting with the mobile imaging platform still demonstrated 100 times greater sensitivity than could be obtained with a commercial rapid influenza test kit.

"I wanted to produce a useful tool for inaccessible or less-affluent communities that can help in the fight against diseases such as influenza," said first author Dr. Yoshihiro Minagawa, chief researcher in the faculty of engineering at the University of Tokyo. "Diagnosis is a critical factor of disease prevention. Our device paves the way for better access to essential diagnostic tools."

"Given two equal samples containing influenza, our system detected about 60% of the number of viruses as the fluorescence microscope. But it is much faster at doing so and more than adequate to produce good estimates for accurate diagnoses," said Dr. Minagawa. "What is really amazing is that our device is about 100 times more sensitive than a commercial rapid influenza test kit, and it is not just limited to that kind of virus. We also wish to add other biomarkers such as nucleic acids -- like DNA -- to the options of things the device can detect. This way we can maximize its usefulness to those on the front line of disease prevention, helping to save lives."

The smartphone-based virus detector was described in the July 17, 2019, online edition of the journal Lab on a Chip.

Related Links:
University of Tokyo


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Electrolyte Analyzer
BKE-B
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: LVOne uses blood-based biomarkers to detect stroke and identify large vessel occlusion before hospital arrival, providing objective results earlier than traditional assessments. (Photo courtesy of UpFront Diagnostics)

First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage

Rapid stroke identification before hospital arrival is critical because treatment efficacy declines with every minute of delay. However, definitive assessment typically requires hospital-based imaging,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Ebola remains a rapidly evolving public health threat with high mortality, underscoring the need for timely diagnosis and decentralized testing closer to patients (Image Credit: Adobe Stock)

Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories

Co-Diagnostics, Inc. (Salt Lake City, UT, USA) and ReadyGo Diagnostics Ltd. (Bath, UK) have initiated a collaboration to evaluate ReadyGo’s GoCollect with the Co-Dx PCR platform for blood-based molecular... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.